These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 15812725)

  • 21. Cardiac responses to calcium sensitizers and isoproterenol in intact guinea pig hearts. Effects on cyclic AMP levels, protein phosphorylation, myoplasmic calcium concentration, and left ventricular function.
    Kristof E; Szigeti G; Papp Z; Bodi A; Facsko A; Kovacs L; Papp JG; Kranias EG; Edes I
    Ann N Y Acad Sci; 1998 Sep; 853():316-9. PubMed ID: 10603968
    [No Abstract]   [Full Text] [Related]  

  • 22. Inotropic therapy of heart failure. Editorial comments on: Vasodilation and mechanoenergetic inefficiency dominates the effect of the "Ca2+ sensitizer" MCI-154 in intact pigs.
    Duncker DJ; Verdouw PD
    Scand Cardiovasc J; 2002 May; 36(3):131-5. PubMed ID: 12079634
    [No Abstract]   [Full Text] [Related]  

  • 23. Effects of levosimendan on markers of kidney function in patients with acutely decompensated heart failure and renal impairment.
    Rafouli-Stergiou P; Parissis JT; Farmakis D; Bistola V; Frogoudaki A; Vasiliadis K; Ikonomidis I; Paraskevaidis I; Kremastinos D; Filippatos G; Lekakis J
    J Cardiovasc Med (Hagerstown); 2017 Oct; 18(10):771-773. PubMed ID: 25643197
    [No Abstract]   [Full Text] [Related]  

  • 24. Cardiac Ca2+ signaling and Ca2+ sensitizers.
    Endoh M
    Circ J; 2008 Dec; 72(12):1915-25. PubMed ID: 18981594
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Calcium mobilizers and calcium sensitizers].
    Arai M
    Nihon Rinsho; 2011 Nov; 69 Suppl 9():417-22. PubMed ID: 22724240
    [No Abstract]   [Full Text] [Related]  

  • 26. Calcium sensitizer agents: a new class of inotropic agents in the treatment of decompensated heart failure.
    Perrone SV; Kaplinsky EJ
    Int J Cardiol; 2005 Sep; 103(3):248-55. PubMed ID: 16098385
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Levosimendan: a new option in acute septic cardiac failure?
    Powell BP; De Keulenaer B
    Emerg Med Australas; 2007 Apr; 19(2):177; author reply 177-8. PubMed ID: 17448109
    [No Abstract]   [Full Text] [Related]  

  • 28. Levosimendan in heart failure after surgical repair of cardiac rupture.
    Torrado H; Ventura JL; Ruiz-Majoral A; Farrero E; Rodriguez-Castro D; Carrio ML; Miralles A
    Minerva Cardioangiol; 2009 Feb; 57(1):137-8. PubMed ID: 19202525
    [No Abstract]   [Full Text] [Related]  

  • 29. [Troponin component of the cardiotropic effect of levosimendan on the isolated myocardium from patients with chronic coronary insufficiency].
    Afanas'ev SA; Timofeev VIu; Karpov RS
    Biull Eksp Biol Med; 1999 Oct; 128(10):457-8. PubMed ID: 10599510
    [No Abstract]   [Full Text] [Related]  

  • 30. Mechanisms and use of calcium-sensitizing agents in the failing heart.
    Kass DA; Solaro RJ
    Circulation; 2006 Jan; 113(2):305-15. PubMed ID: 16418450
    [No Abstract]   [Full Text] [Related]  

  • 31. Levosimendan in cardiogenic shock: the magic drug for every patient?
    Smetana P; Geppert A
    Crit Care Med; 2007 Dec; 35(12):2862-4. PubMed ID: 18043208
    [No Abstract]   [Full Text] [Related]  

  • 32. The calcium sensitizer levosimendan improves carbon monoxide poisoning related stunned myocardium: a cardiac magnetic resonance study.
    Rocco M; Carbone I; Morelli A; Palantonio P; Rossi S; Spadetta G; Passariello R; Pietropaoli P
    Acta Anaesthesiol Scand; 2006 Aug; 50(7):897-8. PubMed ID: 16879479
    [No Abstract]   [Full Text] [Related]  

  • 33. Levosimendan restores both systolic and diastolic cardiac performance in lipopolysaccharide-treated rabbits: comparison with dobutamine and milrinone.
    Barraud D; Faivre V; Damy T; Welschbillig S; Gayat E; Heymes C; Payen D; Shah AM; Mebazaa A
    Crit Care Med; 2007 May; 35(5):1376-82. PubMed ID: 17414729
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Calcium sensitizer: characteristics, mechanisms of action, pharmacokinetics, indication, contraindication, clinical data, and side effects].
    Shinagawa H; Izumi T
    Nihon Rinsho; 2007 May; 65 Suppl 5():57-60. PubMed ID: 17569308
    [No Abstract]   [Full Text] [Related]  

  • 35. European experience on the practical use of levosimendan in patients with acute heart failure syndromes.
    Follath F; Franco F; Cardoso JS
    Am J Cardiol; 2005 Sep; 96(6A):80G-5G. PubMed ID: 16181827
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Levosimendan: a novel inotropic agent for treatment of acute, decompensated heart failure.
    Earl GL; Fitzpatrick JT
    Ann Pharmacother; 2005 Nov; 39(11):1888-96. PubMed ID: 16219899
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-inflammatory effects of levosimendan in decompensated heart failure: impact on weight loss and anemia.
    Parissis JT; Farmakis D; Kremastinos DT
    Am J Cardiol; 2005 Apr; 95(7):923-4. PubMed ID: 15781038
    [No Abstract]   [Full Text] [Related]  

  • 38. Could Ca2+ sensitizers rescue patients from chronic congestive heart failure?
    Endoh M
    Br J Pharmacol; 2007 Apr; 150(7):826-8. PubMed ID: 17325657
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of levosimendan on right ventricular systolic and diastolic functions in patients with ischaemic heart failure.
    Duygu H; Ozerkan F; Zoghi M; Nalbantgil S; Yildiz A; Akilli A; Akin M; Nazli C; Ergene O
    Int J Clin Pract; 2008 Feb; 62(2):228-33. PubMed ID: 17949428
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Direct effects of pimobendan on cardiac myofilaments.
    Fujino K; Sperelakis N; Solaro RJ
    Prog Clin Biol Res; 1989; 315():602-3. PubMed ID: 2798516
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.